U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 million

cafead

Administrator
Staff member
  • cafead   Jul 14, 2023 at 10:22: AM
via The Institute for Clinical and Economic Review, an influential drug pricing watchdog, raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals/CRISPR Therapeutics and Bluebird Bio.

article source